Institutional shares held 992 Million
10.5M calls
9.75M puts
Total value of holdings $91.8B
$969M calls
$902M puts
Market Cap $117B
1,253,369,984 Shares Out.
Institutional ownership 79.15%
# of Institutions 1,926


Latest Institutional Activity in GILD

Top Purchases

Q3 2024
Wellington Management Group LLP Shares Held: 34.6M ($3.23B)
Q3 2024
Citadel Advisors LLC Shares Held: 5.02M ($469M)
Q3 2024
Amundi Shares Held: 13.6M ($1.27B)
Q3 2024
Point72 Asset Management, L.P. Shares Held: 2.31M ($215M)
Q3 2024
Pictet Asset Management Holding Sa Shares Held: 4.26M ($398M)

Top Sells

Q3 2024
Pacer Advisors, Inc. Shares Held: 782K ($73M)
Q3 2024
Two Sigma Advisers, LP Shares Held: 2.49M ($232M)
Q3 2024
Two Sigma Investments, LP Shares Held: 699K ($65.3M)
Q3 2024
D. E. Shaw & Co., Inc. Shares Held: 741K ($69.2M)
Q3 2024
Morgan Stanley Shares Held: 17.2M ($1.61B)

About GILD

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.


Insider Transactions at GILD

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
1.08M Shares
From 17 Insiders
Grant, award, or other acquisition 473K shares
Exercise of conversion of derivative security 602K shares
Sell / Disposition
769K Shares
From 11 Insiders
Payment of exercise price or tax liability 215K shares
Open market or private sale 554K shares

Track Institutional and Insider Activities on GILD

Follow GILEAD SCIENCES, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells GILD shares.

Notify only if

Insider Trading

Get notified when an Gilead Sciences, Inc. insider buys or sells GILD shares.

Notify only if

News

Receive news related to GILEAD SCIENCES, INC.

Track Activities on GILD